Skip to main content
SpringerLink
Log in

Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents

  • Multiple Myeloma (P Kapoor, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Advances in therapy in multiple myeloma have resulted in significant improvements in patient outcomes; however, relapse remains problematic. Strategies to improve outcomes following autologous stem cell transplantation (ASCT) include consolidation to intensify therapy and improve depth of response and maintenance therapy to achieve long-term disease control. Immunomodulatory drugs (IMiDs), including thalidomide and lenalidomide, are appealing as maintenance therapy given their oral administration; however, the cumulative toxicities of thalidomide have limited its efficacy in maintenance therapy. Maintenance lenalidomide is better tolerated, and multiple studies have demonstrated an improvement in progression-free survival (PFS), but its impact on overall survival (OS) remains controversial. Additional concerns regarding the risk of second primary malignancies and significant cost of long-term lenalidomide therapy have also been raised. Proteasome inhibitors, particularly, bortezomib have also been incorporated in consolidation and maintenance regimens alone or in combination with an IMiD. Preliminary studies have suggested bortezomib maintenance may benefit patients with adverse cytogenetics, including t(4;14) and deletion 17p. Determination of the optimal consolidation and maintenance regimen and duration of therapy post-transplantation is a focus of several ongoing randomized studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Kapoor P, Kumar SK, Dispenzieri A, Lacy MQ, Buadi F, Dingli D, et al. Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol : Off J Am Soc Clin Oncol. 2013;31(36):4529–35. This study showed that depth of response results in improved long term outcome.

    Article  Google Scholar 

  2. Paiva B, Gutierrez NC, Rosinol L, Vidriales MB, Montalban MA, Martinez-Lopez J, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. Blood. 2012;119(3):687–91.

    Article  CAS  PubMed  Google Scholar 

  3. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013;31(20):2540–7.

    Article  PubMed  Google Scholar 

  4. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood. 2014;123(20):3073–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rawstron AC, Gregory WM, de Tute RM, Davies FE, Bell SE, Drayson MT, et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood. 2015;125(12):1932–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood. 2008;112(10):4017–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, et al. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Br J Haematol. 2015;171(3):344–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, et al. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics’ impact on survival. Leukemia. 2015;29(3):689–95.

    Article  CAS  PubMed  Google Scholar 

  9. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495–502.

    Article  CAS  PubMed  Google Scholar 

  10. The Myeloma Trialists’ Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol. 2001;113(4):1020–34.

    Article  Google Scholar 

  11. Mellqvist UH, Gimsing P, Hjertner O, Lenhoff S, Laane E, Remes K, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121(23):4647–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120(1):9–19.

    Article  CAS  PubMed  Google Scholar 

  13. Tacchetti P, Pantani L, De Stefano V, Zamagni E, Peccatori J, Pezzi A, et al. Superior PFS2 with VTD Vs TD for newly diagnosed, transplant eligible, Multiple Myeloma (MM) patients: updated analysis of Gimema MMY-3006 study. ASH Ann Meet Abstr. 2014;124(21):196.

    Google Scholar 

  14. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28(12):2077–84.

    Article  CAS  PubMed  Google Scholar 

  15. Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chretien ML, et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia. 2013;27(11):2242–4.

    Article  CAS  PubMed  Google Scholar 

  16. Straka C, Vogel M, Muller J, Kropff M, Metzner B, Langer C, et al. Results from two phase III studies of bortezomib consolidation vs observation post-transplant in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(suppl):Abstr 8511.

  17. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014;32(25):2712–7.

    Article  CAS  PubMed  Google Scholar 

  18. Attal M, Lauwers-Cances V, Hulin C, Facon T, Caillot D, Escoffre M, et al. Autologous transplantation for multiple myeloma in the era of new drugs: a phase III study of the intergroupe francophone du myelome (IFM/DFCI 2009 Trial). Blood. 2015;126(23):Abstr 391.

  19. Belch A, Shelley W, Bergsagel D, Wilson K, Klimo P, White D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer. 1988;57(1):94–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mandelli F, Avvisati G, Amadori S, Boccadoro M, Gernone A, Lauta VM, et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med. 1990;322(20):1430–4.

    Article  CAS  PubMed  Google Scholar 

  21. Drayson MT, Chapman CE, Dunn JA, Olujohungbe AB, Maclennan IC. MRC trial of alpha2b-interferon maintenance therapy in first plateau phase of multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;101(1):195–202.

    Article  CAS  PubMed  Google Scholar 

  22. Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, et al. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol. 1998;16(3):890–6.

    CAS  PubMed  Google Scholar 

  23. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006;108(10):3289–94.

    Article  CAS  PubMed  Google Scholar 

  24. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E, Hollmig K, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood. 2008;112(8):3115–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115(6):1113–20.

    Article  CAS  PubMed  Google Scholar 

  26. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7–15.

    Article  CAS  PubMed  Google Scholar 

  27. Stewart AK, Trudel S, Bahlis NJ, White D, Sabry W, Belch A, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 2013;121(9):1517–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC, Mercante DR, et al. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol. 2012;87(10):948–52.

    Article  CAS  PubMed  Google Scholar 

  29. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J, Moreau P, et al. Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. J Clin Oncol. 2010;28(7):1209–14.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. J Natl Cancer Inst. 2016 Mar;108(3).

  31. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91.

    Article  CAS  PubMed  Google Scholar 

  32. Attal M, Lauwers-Cances V, Marit G, Caillot D, Facon T, Hulin C, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: follow-up analysis of the IFM 2005–02 Trial. ASH Annual Meeting Abstracts. 2013;122(406).

  33. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. McCarthy P, Owzar K, Hofmeister C. Analysis of overall survival (OS) in the context of cross-over from placebo to lenalidomide and the incidence of second primary malignancies (SPM) in the phase III study of lenalidomide versus placebo maintenance therapy following autologous stem cell transplant (ASCT) for multiple myeloma (MM) CALGB (Alliance) ECOG BMTCTN. Clin Lymphoma Myeloma. 2013;Suppl 1:S28.

  35. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333–42.

    Article  CAS  PubMed  Google Scholar 

  36. Palumbo A, Cavallo F, Gay F, Di Raimondo F, Ben Yehuda D, Petrucci MT, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905. Showed both PFS and OS benefit with ASCT, and PFS benefit with lenalidomide maintenance, but no OS benefit.

    Article  PubMed  Google Scholar 

  37. Singh PP, Kumar S, Laplant B, Gertz M, Dispenzieri A, Bergsagel PL, et al. Lenalidomide maintenance therapy in multiple myeloma: a meta-analysis of randomized trials. Blood. 2013;122(21):407.

    Google Scholar 

  38. Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol : Off J Am Soc Clin Oncol. 2012;30(24):2946–55.

    Article  CAS  Google Scholar 

  39. Rosinol L, Oriol A, Teruel AI, Hernandez D, Lopez-Jimenez J, de la Rubia J, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120(8):1589–96.

    Article  CAS  PubMed  Google Scholar 

  40. Kumar S, Berdeja JG, Niesvizky R, Lonial S, Laubach J, Hamadani M, et al. Long-term Ixazomib maintenance is tolerable and improves depth of response following Ixazomib-Lenalidomide-Dexamethasone induction in patients with previously untreated multiple myeloma: phase 2 study results. Blood. 2014;124(21):Abst 82.

  41. Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940–8.

    Article  CAS  PubMed  Google Scholar 

  42. Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, et al. Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients. Leukemia. 2014;28(3):690–3.

    Article  CAS  PubMed  Google Scholar 

  43. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906–17.

    Article  CAS  PubMed  Google Scholar 

  44. Hulin C, Facon T, Shustik C, Belch A, Petrucci MT, Duhrsen U, et al. Effect of age on efficacy and safety outcomes in patients with newly diagnosed multiple myeloma receiving Lenalidomide and low-dose Dexamethasone (Rd): the first trial. Blood. 2014;124(21):81.

    Google Scholar 

  45. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–69.

    Article  CAS  PubMed  Google Scholar 

  46. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Korde N, Roschewski M, Zingone A, Kwok M, Manasanch EE, Bhutani M, et al. Treatment with Carfilzomib-Lenalidomide-Dexamethasone with Lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. [Research Support, Non-U.S. Gov’t]. 2015 Sep;1(6):746–54.

  48. Lesokhin A, Ansell S, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Preliminary results of a phase i study of Nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. ASH Ann Meet Abstr. 2014;124(21).

  49. San Miguel J, Mateos M, Shah J, Ocio E, Rodriguez-Otero P, Reece D, et al. Pembrolizumab in combination with Lenalidomide and low-dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023. ASH Ann Meet Abstr. 2015;126(23).

  50. Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005;129(5):687–700.

    Article  CAS  PubMed  Google Scholar 

  51. Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine JD, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011;34(5):409–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Garfall AL, Valderrama M, Lacey SF. Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma [ASCO abstract 8517]. J Clin Oncol. 2015;33(15).

Download references

Author information

Authors and Affiliations

  1. Judy and Bernard Briskin Center for Multiple Myeloma Research, Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, 1500 Duarte Road, Duarte, CA, 91010, USA

    Nitya Nathwani

  2. Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, USA

    Jeremy T. Larsen & Prashant Kapoor

Authors
  1. Nitya Nathwani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeremy T. Larsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prashant Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nitya Nathwani.

Ethics declarations

Conflict of Interest

Nitya Nathwani and Jeremy T. Larsen each declare no potential conflicts of interest.

Prashant Kapoor is a section editor for Current Hematologic Malignancy Reports.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Additional information

This article is part of the Topical Collection on Multiple Myeloma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nathwani, N., Larsen, J.T. & Kapoor, P. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents. Curr Hematol Malig Rep 11, 127–136 (2016). https://doi.org/10.1007/s11899-016-0310-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0310-9

Keywords

Search

Navigation